1-3 of 3
Masha Fridkis-Hareli, PhD
Close
Sort by
Journal Articles

Preclinical Evaluation of RA101495, a Potent Cyclic Peptide Inhibitor of C5 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria

Alonso Ricardo, PhD, Michelle Arata, MS, Steven DeMarco, PhD, Ketki Dhamnaskar, MS, Robert Hammer, PhD, Masha Fridkis-Hareli, PhD, Vaishnavi Rajagopal, PhD, Kathleen Seyb, PhD, Guo-Qing Tang, PhD, Sylvia Tobe, PhD, Douglas Treco, PhD
Journal: Blood
Blood (2015) 126 (23): 939.
https://doi.org/10.1182/blood.V126.23.939.939
Published: 2015
Journal Articles

C3-Mediated Extravascular Hemolysis In Paroxysmal Nocturnal Hemoglobinuria: An In Vitro Model to Dissect Complement C3 Activation Comparing the Effects of Complement Inhibitors Eculizumab, 3E7 and TT30 on C3 Fragment Processing and Hemolysis of PNH Erythrocytes

Antonio M. Risitano, MD, PhD, Caterina Pascariello, Luigi Del Vecchio, MD, Christopher J Horvath, DVM, MS, DACVP, Masha Fridkis-Hareli, PhD, V. Michael Holers, MD, Margaret A Lindorfer, PhD, Ronald P Taylor, PhD
Journal: Blood
Blood (2010) 116 (21): 637.
https://doi.org/10.1182/blood.V116.21.637.637
Published: 2010
Journal Articles

TT30, a Novel Human Complement Inhibitor in Development for Paroxysmal Nocturnal Hemoglobinuria and Other Hemolytic Disorders, Demonstrates Red Blood Cell Surface Targeting and Retention In a Model of Complement Alternative Pathway-Mediated Hemolysis

Masha Fridkis-Hareli, PhD, Michael Storek, PhD, Antonio M. Risitano, MD, PhD, Ante S. Lundberg, MD, Christopher J Horvath, DVM, MS, DACVP, V. Michael Holers, MD
Journal: Blood
Blood (2010) 116 (21): 638.
https://doi.org/10.1182/blood.V116.21.638.638
Published: 2010